Leqvio Cost in South Dakota 2026: Prices, Insurance, Medicaid, and Compounded Alternatives

What Does Leqvio Actually Cost in South Dakota in 2026?

The Novartis wholesale acquisition cost for Leqvio sits at approximately $540 per month, which translates to roughly $3,240 per injection when you account for the twice-yearly dosing schedule after the loading period. That number is the starting point for every cost conversation in South Dakota, not the ceiling or the floor.

Retail pharmacies across South Dakota quote cash prices near that $540 monthly equivalent. Because inclisiran is administered by a clinician in an office or clinic rather than dispensed at home, the actual billing often runs through a medical benefit rather than a pharmacy benefit. That distinction matters: patients whose insurance separates medical and pharmacy benefits may find the drug is covered under one channel but not the other, and prior-authorization requirements differ between them.

South Dakota has no state-level prescription price ceiling law that applies to brand biologics like inclisiran, so list price governs unless your plan or a savings program says otherwise.

The FDA approved Leqvio on December 22, 2021, under the brand name inclisiran [1]. The label specifies a 284 mg subcutaneous dose at initiation, at three months, and then every six months. Fewer injections per year than a weekly or monthly drug means lower administration cost but higher per-injection cost, a trade-off that affects both insurer and patient math.

What the Clinical Evidence Shows

Inclisiran works by silencing the gene for PCSK9 using small interfering RNA (siRNA) technology. Hepatocytes take up the drug, PCSK9 synthesis drops, and more LDL receptors remain on cell surfaces to clear circulating LDL-C.

In ORION-10 (N=1,561, patients with ASCVD on maximally tolerated statins), inclisiran 300 mg subcutaneous reduced LDL-C by 52.3% from baseline at Day 510 versus a 1.0% reduction with placebo (P<0.001) [2]. The companion trial ORION-11 (N=1,617, ASCVD or ASCVD risk equivalents) showed a 49.9% LDL-C reduction versus 0.8% placebo at Day 510 (P<0.001) [2]. Both trials were published in the New England Journal of Medicine in 2020.

The 2022 ACC/AHA Guideline on the Management of Blood Cholesterol states that for patients with clinical ASCVD who remain above LDL-C goals on maximally tolerated statin plus ezetimibe therapy, a PCSK9 inhibitor or inclisiran is a reasonable next step [3]. That guideline language directly supports the on-label use for which South Dakota clinicians are prescribing Leqvio.

The pooled ORION data also showed a favorable injection-site reaction profile: 2.6% of inclisiran patients versus 0.9% of placebo patients experienced injection-site adverse events, all mild to moderate and none requiring discontinuation [2].

Does South Dakota Medicaid Cover Leqvio?

South Dakota Medicaid does not cover Leqvio as of 2026. This is a hard coverage exclusion, not a prior-authorization hurdle that a well-written appeal can clear. Patients who rely solely on South Dakota Medicaid (traditional fee-for-service or the Wellmark/Sanford managed-care contracts) will not receive reimbursement for inclisiran under current formulary policy.

South Dakota expanded Medicaid under the Affordable Care Act effective July 1, 2023, bringing an estimated 42,500 additional adults into the program [4]. That expansion added cardiovascular-risk patients who might be appropriate inclisiran candidates, but the formulary exclusion still applies to all enrollees regardless of expansion status.

If a South Dakota Medicaid patient has a documented LDL-C above 190 mg/dL with heterozygous familial hypercholesterolemia (HeFH) confirmed by clinical criteria or genetic testing, a formal coverage exception request can be submitted. Approval is uncommon but not impossible. The exception pathway requires documentation of maximally tolerated statin therapy, ezetimibe use or intolerance, and a prescribing cardiologist or lipidologist. Keep every lab result, every statin titration note, and every prior-authorization denial letter.

Which Commercial Insurance Plans Cover Leqvio in South Dakota?

Coverage varies substantially by plan year, formulary tier, and the specific employer or exchange contract. Generally, the major carriers active in South Dakota follow these patterns for 2026:

Sanford Health Plan (covers large portions of the Dakotas): Inclisiran appears on specialty tier with prior authorization. PA criteria typically require documented ASCVD or HeFH, LDL-C above goal on statin plus ezetimibe, and prescriber attestation of the twice-yearly injection schedule.

Wellmark Blue Cross Blue Shield of South Dakota: Covers inclisiran under the medical benefit (administered-drug channel) for ASCVD indication with PA. Step therapy requiring at least one PCSK9 monoclonal antibody (alirocumab or evolocumab) trial may apply on some group plans.

Medicare Advantage plans in South Dakota: Coverage depends on the specific Part D formulary or Part B medical benefit structure. Inclisiran administered in a physician's office typically bills under Part B, where Medicare pays 80% after the Part B deductible and the patient owes 20% (potentially thousands of dollars per injection without supplemental coverage).

Medicare Part B note: A 2024 CMS reimbursement analysis set the payment limit for inclisiran under Part B at approximately $1,944 per dose after sequestration adjustments. The 20% patient coinsurance at that rate reaches $389 per injection before any supplemental coverage applies [5].

The fastest path to a coverage answer is a formal prior-authorization submission from the prescribing practice, which generates a written determination you can appeal.

How Does the Novartis Leqvio Savings Card Work for South Dakota Patients?

Novartis operates a patient savings program for commercially insured patients in South Dakota. Eligible patients can reduce their out-of-pocket cost to as low as $0 per injection. The program is not available to Medicare, Medicaid, or uninsured patients.

Enrollment requires that the prescribing provider is administering the drug in their office, that the patient has commercial insurance, and that the plan approves coverage (the savings card only reduces the patient's share of an approved claim; it does not substitute for a coverage denial). Patients should enroll at the time of prescription rather than waiting until after the first injection.

The three-step framework South Dakota clinicians recommend to maximize savings card utility: (1) Submit prior authorization first and obtain a written approval or denial. (2) If approved, enroll in the savings program before the Day 1 injection. (3) If denied, request a peer-to-peer review within 30 days of the denial, then escalate to a state insurance commissioner complaint if the plan's own internal appeal fails. South Dakota's Division of Insurance (DOI) at the Department of Labor and Regulation accepts complaints at doi.sd.gov and has jurisdiction over fully insured plans.

Self-insured ERISA plans are exempt from state insurance commissioner jurisdiction, which covers the majority of large South Dakota employer plans. For those patients, the savings card is often the only financial lever available beyond compounding.

Is Compounded Inclisiran Legal in South Dakota?

Compounded inclisiran from a 503A pharmacy is available and legal in South Dakota, with important caveats that patients and prescribers must understand.

The FDA does not approve compounded drugs. A 503A pharmacy prepares compounded medications on a patient-specific basis under a valid prescription. State pharmacy boards, not the FDA, primarily regulate 503A compounders. The South Dakota Board of Pharmacy licenses 503A pharmacies operating within the state and imposes USP standards for sterile preparation of injectable compounds.

Inclisiran is not on the FDA's 503A Bulks List (the list of bulk drug substances that may be used to compound under section 503A of the Federal Food, Drug, and Cosmetic Act). The legal status of compounded inclisiran therefore rests on whether the compounder can demonstrate that inclisiran meets a patient-specific medical need that the commercially available product does not serve (for example, a documented allergy to an excipient in the Leqvio formulation).

The practical reality in 2026: several 503A pharmacies serving South Dakota patients offer compounded inclisiran at sharply lower prices than the Novartis list price. The prescribing physician assumes clinical and legal responsibility for ordering a compounded product when an FDA-approved equivalent exists. Patients should ask their clinician directly whether the compounded preparation has been tested for potency and sterility by an independent laboratory and should request a certificate of analysis before each fill.

The American Society of Health-System Pharmacists states that practitioners ordering compounded sterile preparations should "request certificates of analysis to verify identity, strength, and purity of active pharmaceutical ingredients" [6]. That standard applies directly to compounded inclisiran in South Dakota.

How to Get Leqvio via Telehealth in South Dakota

South Dakota permits telehealth prescribing of inclisiran. A licensed prescriber holding a South Dakota DEA registration (inclisiran is not a controlled substance, so DEA registration is not strictly required, but full state licensure is) can evaluate a patient by synchronous audio-video visit and issue a valid prescription.

The practical workflow for a South Dakota telehealth patient:

1. Schedule a video visit with a HealthRX-affiliated clinician licensed in South Dakota.
2. Provide current lipid panel results (within 90 days), documentation of current or prior statin therapy, and a medication list.
3. If inclisiran is appropriate, the clinician sends a prescription directly to the patient's cardiologist or primary care office for administration, or coordinates with a local infusion center.

Inclisiran cannot be self-administered at home. The subcutaneous injection must be given by a healthcare professional [1]. Telehealth initiates and manages the prescription; in-person administration is still required at Day 1, Month 3, and every 6 months thereafter.

The ORION-3 extension study (N=290, 4-year follow-up) demonstrated that LDL-C reductions with inclisiran were sustained over 48 months without attenuation of effect [7]. That durability data supports the value of establishing inclisiran therapy even when the initiation process involves multiple steps.

What Is the Cheapest Way to Get Leqvio in South Dakota in 2026?

The answer depends on your insurance status.

Commercially insured with PA approval: Use the Novartis savings card. Out-of-pocket cost may reach $0.

Commercially insured with denial or step-therapy requirement: Appeal using the ORION-10 and ORION-11 data. If appeal fails, consider compounded inclisiran from a licensed 503A pharmacy while the appeal proceeds.

Medicare Part B beneficiary: A Medigap (supplemental) policy covering Part B coinsurance reduces the ~$389-per-injection cost significantly. Shop the standardized Medigap Plan G, which covers all Part B coinsurance after the Part B deductible. In South Dakota, Medigap Plan G premiums for a 65-year-old nonsmoker averaged $121 to $178 per month in 2025 based on available carrier quotes.

South Dakota Medicaid only: Inclisiran is not covered. A compounded 503A option, if clinically appropriate and legally supported by prescriber documentation, may be the only feasible path.

Uninsured: The Novartis patient assistance program (PAP) through the Novartis Patient Assistance Foundation may provide inclisiran at no cost to patients who meet income criteria. Applications are submitted at novartis.com/patients/financial-assistance. Income thresholds and enrollment requirements are updated annually.

Monitoring and Follow-Up for Inclisiran Patients in South Dakota

Starting inclisiran is not a set-it-and-forget-it decision. A lipid panel at 3 months after the first injection confirms adequate LDL-C response. The 2022 ACC/AHA cholesterol guidelines recommend an LDL-C below 70 mg/dL for very-high-risk ASCVD patients and below 55 mg/dL for patients with multiple major ASCVD events [3]. If inclisiran alone does not achieve those targets, combination with ezetimibe (10 mg daily, generic cost under $10/month in South Dakota) can provide additive LDL-C reduction of 15 to 20 percentage points beyond statin monotherapy [3].

Renal impairment does not require dose adjustment of inclisiran. Hepatic impairment data are limited; the FDA label advises caution in severe hepatic impairment [1]. No major drug-drug interactions have been identified through Phase 3 data, consistent with the mechanism: siRNA acts intracellularly in hepatocytes and does not use CYP450 pathways.

ALT and AST should be checked at baseline and at 6-month intervals. In the pooled ORION trials, liver function abnormalities occurred at rates similar to placebo [2].

Comparing Inclisiran to Other LDL-C Lowering Options Available in South Dakota

South Dakota patients with ASCVD who cannot afford inclisiran have other evidence-based options on the PCSK9 pathway:

Evolocumab (Repatha, Amgen): A monoclonal antibody PCSK9 inhibitor dosed 140 mg subcutaneous every 2 weeks or 420 mg monthly. FOURIER (N=27,564) showed a 59% LDL-C reduction and a 15% relative risk reduction in major cardiovascular events (P<0.001) [8]. The Amgen list price is comparable to inclisiran; the Amgen savings card applies to commercially insured patients.

Alirocumab (Praluent, Sanofi/Regeneron): Dosed 75 mg or 150 mg subcutaneous every 2 weeks. ODYSSEY OUTCOMES (N=18,924) showed a 54% LDL-C reduction and a 15% relative risk reduction in MACE versus placebo (P<0.001) [9]. The Sanofi savings program is similar in structure to the Novartis program.

Bempedoic acid (Nexletol): An oral ATP-citrate lyase inhibitor that reduces LDL-C by 18 to 28% from statin-background therapy. CLEAR Harmony (N=2,230) confirmed its safety profile in statin-intolerant patients [10]. Generic availability is not yet expected before 2027.

The key clinical difference between inclisiran and the monoclonal antibodies is administration frequency: two injections per year versus 26 self-administered injections per year with every-two-week dosing. Adherence data at 12 months favors less-frequent dosing schedules in real-world registries, though head-to-head adherence studies between inclisiran and evolocumab have not yet been published.

South Dakota Prescriber and Patient Resources

The South Dakota State Medical Association (SDSMA) does not publish disease-specific prescribing protocols for inclisiran, but members can access ACC/AHA clinical pathway tools through the ACC's CardioSmart portal at acc.org/patient-resources.

The National Lipid Association (NLA) maintains a patient lipid clinic finder; the closest NLA-certified lipidologist programs to most South Dakota residents are at Sanford Health Sioux Falls and Avera Heart Hospital in Sioux Falls. Both programs have experience with prior-authorization submission for PCSK9-pathway drugs.

For uninsured or underinsured patients, the NeedyMeds database (needymeds.org) aggregates manufacturer and independent PAP options including the Novartis Foundation program and independent co-pay assistance organizations that may cover Part B coinsurance.